Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60495 | 0.82 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2MDM4 | |
| SCHEMBL1880390 | 0.81 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2MDM4 | |
| SCHEMBL26941528 | 0.81 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2MDM4 | |
| SCHEMBL27872882 | 0.81 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2MDM4 | |
| SCHEMBL31437105 | 0.80 | KMT2A (0.46) | KMT2AFABP5FABP7EPHX2MDM4 | |
| SCHEMBL18614227 | 0.80 | KMT2A (0.46) | KMT2AFABP5FABP7EPHX2MDM4 | |
| SCHEMBL18614222 | 0.80 | KMT2A (0.46) | KMT2AFABP5FABP7EPHX2MDM4 | |
| SCHEMBL31540857 | 0.80 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2MDM4 | |
| SCHEMBL4690511 | 0.80 | KMT2A (0.47) | KMT2AFABP5FABP7EPHX2MDM4 | |
| SCHEMBL5496880 | 0.80 | KMT2A (0.47) | KMT2AFABP5FABP7EPHX2MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200316214-A1 | ANTI-CANCER COMPOUNDS AND CONJUGATES THEREOF | SIRENAS LLC (US) | 2020-10-08 | — | — | US | disclosed |
| US-10722593-B2 | Anti-cancer compounds and conjugates thereof | SIRENAS LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-20180296688-A1 | ANTI-CANCER COMPOUNDS AND CONJUGATES THEREOF | SIRENAS LLC | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10722593-B2 | Anti-cancer compounds and conjugates thereof | DDOST, DGKG, DGKB | KMT2A 3654/4885FABP5 1685/4885FABP7 237/4885 |
| US-20200316214-A1 | ANTI-CANCER COMPOUNDS AND CONJUGATES THEREOF | GLS, BCL9, GLI1 | KMT2A 1577/4885FABP5 3845/4885FABP7 991/4885 |
| US-20180296688-A1 | ANTI-CANCER COMPOUNDS AND CONJUGATES THEREOF | DDOST, DGKG, DGKB | KMT2A 3654/4885FABP5 1685/4885FABP7 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.